KR101951511B1 - 레바미피드와 누액 유지 작용을 갖는 약제를 포함하는 전안부 질환 치료제 - Google Patents

레바미피드와 누액 유지 작용을 갖는 약제를 포함하는 전안부 질환 치료제 Download PDF

Info

Publication number
KR101951511B1
KR101951511B1 KR1020147014332A KR20147014332A KR101951511B1 KR 101951511 B1 KR101951511 B1 KR 101951511B1 KR 1020147014332 A KR1020147014332 A KR 1020147014332A KR 20147014332 A KR20147014332 A KR 20147014332A KR 101951511 B1 KR101951511 B1 KR 101951511B1
Authority
KR
South Korea
Prior art keywords
rebamipide
leakage
administration
salt
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147014332A
Other languages
English (en)
Korean (ko)
Other versions
KR20140087030A (ko
Inventor
야스히로 다케지
히데오 나카시마
히로키 우라시마
히사시 시노하라
유키 히라타
Original Assignee
오츠카 세이야쿠 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47215697&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101951511(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 오츠카 세이야쿠 가부시키가이샤 filed Critical 오츠카 세이야쿠 가부시키가이샤
Publication of KR20140087030A publication Critical patent/KR20140087030A/ko
Application granted granted Critical
Publication of KR101951511B1 publication Critical patent/KR101951511B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
KR1020147014332A 2011-11-01 2012-10-31 레바미피드와 누액 유지 작용을 갖는 약제를 포함하는 전안부 질환 치료제 Active KR101951511B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011240177 2011-11-01
JPJP-P-2011-240177 2011-11-01
PCT/JP2012/078769 WO2013065866A1 (en) 2011-11-01 2012-10-31 A medicament for treating anterior eye disease comprising rebamipide and a tear-retaining agent

Publications (2)

Publication Number Publication Date
KR20140087030A KR20140087030A (ko) 2014-07-08
KR101951511B1 true KR101951511B1 (ko) 2019-02-22

Family

ID=47215697

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147014332A Active KR101951511B1 (ko) 2011-11-01 2012-10-31 레바미피드와 누액 유지 작용을 갖는 약제를 포함하는 전안부 질환 치료제

Country Status (19)

Country Link
US (1) US20140294991A1 (enExample)
EP (1) EP2773350A1 (enExample)
JP (1) JP6060168B2 (enExample)
KR (1) KR101951511B1 (enExample)
CN (1) CN103945846A (enExample)
AR (1) AR088585A1 (enExample)
AU (1) AU2012333448A1 (enExample)
BR (1) BR112014010376A2 (enExample)
CA (1) CA2851095A1 (enExample)
CO (1) CO6960545A2 (enExample)
EA (1) EA201490721A1 (enExample)
HK (1) HK1198811A1 (enExample)
IL (1) IL231922A0 (enExample)
IN (1) IN2014CN03123A (enExample)
MX (1) MX2014005209A (enExample)
PH (1) PH12014500967A1 (enExample)
SG (1) SG11201401502TA (enExample)
TW (1) TW201322982A (enExample)
WO (1) WO2013065866A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6081173B2 (ja) * 2011-12-12 2017-02-15 ロート製薬株式会社 眼科用水性組成物
TW201417814A (zh) * 2012-09-28 2014-05-16 Otsuka Pharma Co Ltd 包括瑞巴派特之醫藥組成物
JP6267003B2 (ja) * 2014-02-27 2018-01-24 参天製薬株式会社 ジクアホソルまたはその塩およびレバミピドまたはその塩を組み合わせたことを特徴とする涙液分泌促進剤
JP2017052723A (ja) * 2015-09-10 2017-03-16 株式会社Ｌｔｔバイオファーマ ドライアイ改善剤
KR20170039347A (ko) 2015-10-01 2017-04-11 삼진제약주식회사 레바미피드를 함유하는 신규한 점안 조성물 및 이의 제조방법
GB201618175D0 (en) * 2016-10-27 2016-12-14 Warneford Healthcare Ltd Pharmaceutical compositions
KR101840256B1 (ko) * 2017-09-21 2018-03-21 대우제약 주식회사 레바미피드를 함유하는 새로운 안구건조증 치료용 점안 조성물 및 이의 가용화 및 안정화 방법
KR101923519B1 (ko) 2018-06-26 2019-02-27 대우제약 주식회사 레바미피드를 함유하는 안구 건조증 치료용 수용성 다회용 점안제 조성물 및 이의 가용화 및 안정화 방법
KR20200019451A (ko) 2018-08-14 2020-02-24 대우제약 주식회사 레바미피드를 함유하는 안구 건조증 치료용 수용성 다회용 점안제 조성물 및 이의 가용화 및 안정화 방법
CN112839641A (zh) 2018-12-26 2021-05-25 狮王株式会社 眼科用组合物
WO2023054669A1 (ja) * 2021-09-30 2023-04-06 ロート製薬株式会社 眼科組成物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6060486A (en) 1995-10-12 2000-05-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivative for curing ophthalmological diseases
WO2006052018A1 (en) 2004-11-15 2006-05-18 Otsuka Pharmaceutical Co., Ltd. Aqueous ophthalmic suspension of crystalline rebamipide

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6084225A (ja) * 1983-10-17 1985-05-13 Hiroko Shimizu 点眼剤
JPH0723317B2 (ja) * 1988-03-17 1995-03-15 生化学工業株式会社 角膜上皮層障害症治療剤
JP3093661B2 (ja) * 1995-10-12 2000-10-03 大塚製薬株式会社 眼疾患治療剤
US8388995B1 (en) * 2006-02-03 2013-03-05 Auburn University Controlled and extended delivery of hyaluronic acid and comfort molecules via a contact lens platform
TWI415629B (zh) 2006-10-26 2013-11-21 Otsuka Pharma Co Ltd 含有瑞巴匹特之水性醫藥懸浮物及其製造方法
US8158679B2 (en) * 2006-12-11 2012-04-17 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of L-carnitine for the preparation of a medicament in the form of eye-drops for treating corneal diseases
WO2008074853A1 (en) * 2006-12-21 2008-06-26 Novartis Ag Ophthalmic rebamipide solution
TWI495634B (zh) * 2008-06-19 2015-08-11 Otsuka Pharma Co Ltd 醫藥組成物
US20120003296A1 (en) * 2010-07-01 2012-01-05 Shantha Totada R New methods of treating dry eye syndrome
US20110021974A1 (en) * 2010-10-05 2011-01-27 Shantha Totada R Retinitis pigmentosa treatment and prophalaxis
US20110052678A1 (en) * 2010-11-05 2011-03-03 Shantha Totada R Method for treating age related macular degeneration

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6060486A (en) 1995-10-12 2000-05-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivative for curing ophthalmological diseases
WO2006052018A1 (en) 2004-11-15 2006-05-18 Otsuka Pharmaceutical Co., Ltd. Aqueous ophthalmic suspension of crystalline rebamipide

Also Published As

Publication number Publication date
AR088585A1 (es) 2014-06-18
EP2773350A1 (en) 2014-09-10
TW201322982A (zh) 2013-06-16
JP6060168B2 (ja) 2017-01-11
HK1198811A1 (en) 2015-06-12
MX2014005209A (es) 2014-05-28
IL231922A0 (en) 2014-05-28
CN103945846A (zh) 2014-07-23
EA201490721A1 (ru) 2014-08-29
US20140294991A1 (en) 2014-10-02
SG11201401502TA (en) 2014-09-26
KR20140087030A (ko) 2014-07-08
PH12014500967A1 (en) 2019-10-07
IN2014CN03123A (enExample) 2015-07-03
JP2014532641A (ja) 2014-12-08
WO2013065866A1 (en) 2013-05-10
CA2851095A1 (en) 2013-05-10
AU2012333448A1 (en) 2014-05-22
CO6960545A2 (es) 2014-05-30
BR112014010376A2 (pt) 2017-04-25

Similar Documents

Publication Publication Date Title
KR101951511B1 (ko) 레바미피드와 누액 유지 작용을 갖는 약제를 포함하는 전안부 질환 치료제
Burgalassi et al. Development of a simple dry eye model in the albino rabbit and evaluation of some tear substitutes
US6569903B2 (en) Ophthalmic compositions
KR100889170B1 (ko) 안구 건조의 치료에 있어서 리멕솔론의 용도
AU2011282683B2 (en) Preservative free brimonidine and timolol solutions
CN101111253A (zh) 眼病治疗剂
JP2025513090A (ja) 眼疾患の治療のためのミコフェノール酸及び／又はベタメタゾンの医薬組成物
CN101175487A (zh) 角膜结膜病变的预防或治疗剂
WO2016014437A1 (en) Ophthalmic compositions of rifamycins and uses thereof
IL259562A (en) Aminophosphinic derivatives for preventing and treating eye pain
US20050009902A1 (en) Remedies for pruritus
MXPA03011613A (es) Composicion oftalmica que contiene n-acetil-cisteina para el trtamiento de sindrome de ojo seco.
JP2011144111A (ja) 軸性近視の予防または治療剤
DK3229780T3 (en) Ophthalmic composition for use in the treatment of dry eye syndrome
ES2334368T3 (es) Procedimiento de tratamiento de trastornos de ojo seco y uveitis.
ITUB20152818A1 (it) Formulazioni oftalmiche a base di oligosaccaridi
ITRM970613A1 (it) Uso della flunarizina nella terapia topica del glaucoma
JP2019070026A (ja) 外用剤
KR20200080493A (ko) 효과 지속성 점안제 조성물
JP2023038930A (ja) 眼表面薬物滞留化剤およびこれを含む点眼剤、並びに、これらの剤を用いた眼表面薬物滞留方法および眼科疾患治療方法
CN115554297A (zh) 一种金雀花碱的新医药用途及其药物制剂
CA2567418C (en) Viscous agent for ophthalmic use
JPS63502270A (ja) 散瞳作用を有する眼科用医薬組成物
CA2972212C (en) AGENT AND IMPROVEMENT OF SUBJECTIVE OCULAR SYMPTOMS AND ASSOCIATED METHOD
WO2023048174A1 (ja) 角膜疾患治療剤

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 8